

Basel, 19 April 2016

Roche reports solid sales growth in the first quarter of 2016

- **Group sales up 4%¹ at constant exchange rates, 5% in Swiss francs**
- **Pharmaceuticals Division sales increase 4%, driven by oncology and immunology medicines**
- **Diagnostics Division sales grow 5%, led by immunodiagnostic product demand**
- **US FDA grants priority review for investigational cancer immunotherapy medicine atezolizumab in bladder and lung cancer and breakthrough therapy designation for ocrelizumab in multiple sclerosis**
- **Outlook for 2016 confirmed**

Key figures January – March	In millions of CHF		As % of sales		% change	
	2016	2015	2016	2015	At CER	In CHF
Group sales	12,414	11,833	100	100	+4	+5
Pharmaceuticals Division	9,800	9,322	79	79	+4	+5
United States	4,716	4,392	38	37	+3	+7
Europe	2,319	2,178	19	18	+5	+6
Japan	853	763	7	6	+4	+12
International*	1,912	1,989	15	18	+4	-4
Diagnostics Division	2,614	2,511	21	21	+5	+4

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

Roche CEO Severin Schwan said: “We have started the year with solid growth in both our Pharmaceuticals and Diagnostics Divisions. The marketing applications of important investigational medicines are well underway. The FDA granted priority review for atezolizumab in two indications and breakthrough therapy designation for ocrelizumab in primary progressive multiple sclerosis. Overall, we are on track to meet our full-year targets for 2016.”

¹ Unless otherwise stated, all growth rates in this document are at constant exchange rates (CER: average 2015).

Group

In the first quarter of 2016, Group sales rose 4% to CHF 12.4 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 9.8 billion with Europe growing 5%, driven by Perjeta, MabThera and RoActemra.

Pharmaceuticals sales in the US increased 3%, led by Esbriet, Xolair and HER2-positive breast cancer medicines. The recently launched medicines Cotellic in skin cancer and Alecensa in lung cancer have had a good start. In the US, sales of Tamiflu and Lucentis declined. The main growth contributors in the International region (+4%) were Avastin, MabThera and Herceptin; this growth was partly offset by lower Pegasys sales due to competition from a new generation of treatments. In Japan, sales rose 4% driven by Avastin, HER2 medicines and Alecensa.

In Diagnostics, sales grew 5% to CHF 2.6 billion, driven primarily by strong growth in Asia-Pacific (+16%) and Latin America (+21%). In Europe, the Middle East, and Africa (EMEA) sales increased 1% while they remained stable in North America and declined by 3% in Japan. Strong growth was recorded for the immunodiagnostic, molecular and tissue diagnostics businesses. Diabetes Care sales were impacted by challenging market conditions, especially in North America.

Portfolio progress

In March and April respectively, Roche's lead investigational cancer immunotherapy medicine atezolizumab was granted priority review by the FDA for marketing applications in two indications, advanced bladder cancer and non-small cell lung cancer (NSCLC). Both filings were submitted under FDA breakthrough therapy designations and are based on pivotal phase II data. Atezolizumab is being investigated in a broad phase III clinical programme in solid and hematologic cancers.

The FDA granted breakthrough therapy designation (BTD) for ocrelizumab in primary progressive multiple sclerosis in February. Ocrelizumab is the first investigational medicine to receive BTD in multiple sclerosis. Since 2013, the FDA has granted BTDs for 12 indications of Roche medicines. Roche plans to file ocrelizumab for both relapsing and primary progressive multiple sclerosis in the first half of 2016.

In March, Roche provided an update on two identical phase III studies of lebrikizumab in people with severe asthma. While one study met its primary clinical endpoint, the second did not achieve statistical significance. Roche is analysing the data to help determine next steps in the asthma programme.

In April, the FDA granted Venclexta (venetoclax) accelerated approval for people with a hard-to-treat type of chronic lymphocytic leukemia. Venclexta is the first approved medicine designed to help restore a process in which cells self-destruct by selectively blocking a protein called BCL-2. Venclexta is being jointly developed with AbbVie.

In February, Roche received US approval for Gazyva for the treatment of people with relapsed or rituximab-refractory follicular lymphoma, the most common type of indolent non-Hodgkin lymphoma (NHL), based on phase III results. European approvals are expected later this year. Gazyva is being studied in a large clinical programme in NHL, and phase III data in diffuse large B cell lymphoma, an aggressive type of NHL, are expected later this year.

Outlook for 2016

In 2016, Roche expects sales to grow low- to mid-single digit at constant exchange rates. Core earnings per share are targeted to grow ahead of sales at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.

Pharmaceuticals

Herceptin, Perjeta and Kadcyla (combined +9%), for HER2-positive breast cancer and HER2-positive metastatic gastric cancer (Herceptin only), drove overall sales growth. **Herceptin** sales grew 4%, driven by demand in the International region and the US due to longer duration of treatment in combination with Perjeta. The subcutaneous (SC) formulation of Herceptin is being increasingly adopted across Europe. **Perjeta** (+33%) also performed well, particularly in Europe and the US. Perjeta in combination with Herceptin and chemotherapy is approved in 95 countries as first-line treatment for HER2-positive advanced breast cancer (aBC) and in 60 countries as a neoadjuvant treatment in the HER2-positive early breast cancer setting. **Kadcyla** sales (+11%) were driven primarily by demand in Europe, particularly in Germany and Spain, and in the International region. Kadcyla is approved as a single agent in more than 80 countries worldwide for the second-line treatment of people with HER2-positive aBC.

Avastin (+4%), for advanced colorectal, breast, lung, kidney, cervical and ovarian cancer and glioblastoma (a type of brain tumour), continued to show good sales growth across tumour types. In Latin America, there was a strong sales performance, led by Avastin's growth in the public market. Additionally, this medicine was approved for use in second-line ovarian cancer in Brazil. Growth was also supported by high demand in Asia (+29%), especially China where growth resulted from improved access in the lung and colorectal cancer setting.

MabThera/Rituxan (+3%), for common forms of blood cancer, rheumatoid arthritis and certain types of vasculitis, continued to grow. Growth was driven primarily by significant demand in the International region, particularly in China (+14%), and in Europe.

Gazyva/Gazyvaro (+67%), for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma, delivered a solid sales performance. In CLL, there was good uptake in the US and major European markets.

Gazyva/Gazyvaro is now approved for CLL in more than 70 countries. In the US, Gazyva was approved for use in follicular lymphoma in February.

Alecensa (CHF 29 million) received FDA approval in the US in December 2015 for the treatment of people with ALK-positive advanced NSCLC. Since launch, strong uptake in the US is being driven by use in the second and third-line treatment settings. In Japan, where Alecensa was first launched in 2014, sales continued to grow strongly as the medicine has been increasingly used in patients who have not been previously treated with, have progressed on, or are intolerant to crizotinib.

Esbriet (+96%), for idiopathic pulmonary fibrosis (IPF), saw strong sales growth. Sales reached CHF 127 million in the US and CHF 45 million in Europe, with increasing demand thanks to strong clinical data and expanding patient access. Roche strengthened its leading position in the treatment of IPF in the US and EU.

Actemra/RoActemra (+14%), for rheumatoid arthritis and forms of juvenile idiopathic arthritis, recorded strong growth. Increasing use of Actemra/RoActemra as a single agent and of the SC formulation remained key growth drivers in Europe and the US.

Top-selling pharmaceuticals	Total		United States		Europe		Japan		International*	
	CHFm	%	CHFm	%	CHFm	%	CHFm	%	CHFm	%
MabThera/Rituxan	1,825	3	978	0	479	5	62	12	306	11
Herceptin	1,725	4	651	4	525	2	67	5	482	7
Avastin	1,706	4	775	-2	471	2	192	7	268	27
Perjeta	439	33	224	15	149	65	23	18	43	65
Actemra/RoActemra	386	14	145	12	131	17	60	14	50	10
Tamiflu	367	-6	251	-15	20	78	60	4	36	35
Xolair	356	22	356	22	-	-	-	-	-	-
Lucentis	355	-13	355	-13	-	-	-	-	-	-
Activase/TNKase	276	21	265	21	-	-	-	-	11	13
Tarceva	258	-14	136	-15	48	-18	22	0	52	-14

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

Diagnosics Division

Diagnosics Division January - March		In millions of CHF	% change		As % of sales
			At CER	In CHF	
Sales - Diagnostics Division		2,614	+5	+4	100
Business Areas	Professional Diagnostics	1,519	+7	+7	58
	Molecular Diagnostics	446	+11	+11	17
	Diabetes Care	443	-11	-13	17
	Tissue Diagnostics	206	+13	+16	8
Regions	Europe, Middle East, Africa	1,130	+1	+1	43
	North America	703	0	+3	27
	Asia-Pacific	529	+16	+14	20
	Latin America	157	+21	-1	6
	Japan	95	-3	+3	4

Professional Diagnostics (+7%) was a major contributor to the Division's performance, led by Asia-Pacific, with continued strong growth in China (+24%). The immunodiagnosics business performed strongly, growing 12%, while sales of the clinical chemistry business increased 6%.

In January, the New England Journal of Medicine published a study confirming the prognostic value of Roche's Elecsys sFlt-1/PlGF immunoassay ratio test in predicting which pregnant women are at high risk of developing preeclampsia, one of the leading causes of death and complications for mothers and their babies. Also in January, data on the cardiac troponin T test from Roche were published by the Annals of Emergency Medicine highlighting a novel approach for a more rapid diagnosis of heart attack in patients with acute chest pain. It reduces the observation time needed to rule in or rule out a heart attack to one hour.

In **Molecular Diagnostics**, sales increased by 11%, led by North America and Asia-Pacific. The growth contributors were the sequencing and molecular (+4%) businesses. The molecular business growth was driven by virology (+16%) including the diagnosis and monitoring of hepatitis and HIV viral load as well as HPV screening (+16%). This development was supported by new instruments and tests launched in 2015 as well as a number of tender contracts won last year. In March, the FDA announced that it would allow the use of an investigational Roche test to screen blood donations for the Zika virus. This test can be used under an investigational new drug application for screening donated blood in areas with active mosquito-borne transmission of the Zika virus.

Tissue Diagnostics sales increased 13%, driven by North America. The advanced staining portfolio grew 10% and sales in primary staining increased 24%. This strong increase was supported by the new, fully automated Ventana HE 600 system for hematoxylin and eosin tissue staining, launched in late 2015. Revenues from external personalised healthcare partnerships showed continued strong growth.

Diabetes Care sales decreased 11%, predominantly due to a continued spillover of Medicare prices to commercial plans for the blood glucose monitoring portfolio in the US, leading to a decline in North America of 49%. While EMEA showed a decrease of 6%, strong sales growth was recorded in all other regions (+11% combined).

First Quarter Sales 2016 Conference Call

There will be a conference call for investors and analysts today, **Tuesday 19 April at 2:00 pm CEST**.

Please dial in to the conference call 10-15 min. prior to the scheduled start, using the following numbers:

+41 (0) 58 310 5000 (Europe and ROW)

+44 (0) 203 059 5862 (UK)

+1 (1) 631 570 5613 (USA)

Alternatively a **live audio webcast** can be accessed via <http://ir.roche.com>.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in *in vitro* diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the

majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Additional information

- Investor Update including a full set of tables: <http://www.roche.com/med-cor-2016-04-19.htm>
- Q1 2016 Sales Presentation with appendix: <http://www.roche.com/irp1q16e.pdf>
- Q1 2016 Sales Presentation: <http://www.roche.com/irp1q16e-a.pdf>
- Pharmaceuticals: major clinical and regulatory news flow in 2016: <http://www.roche.com/pharmaAR16e.pdf>
- Diagnostics: key diagnostics product launches in 2016: <http://www.roche.com/diaAR16e.pdf>
- Roche Annual Report 2015 (includes corporate responsibility report): www.roche.com/annual_reports
- Dow Jones Sustainability Indices: www.sustainability-indexes.com

Roche Investor Relations

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Tamer Farhan

Phone: +41 61 68-82552

e-mail: tamer.farhan@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Investor Relations North America

Nina Goworek

Phone: +1 650 467 8737

e-mail: goworek.nina@gene.com

Ekaterine Kortkhonjia Ph.D.

Phone: +1 650 467 5873

e-mail: kortkhonjia.ekaterine@gene.com

Disclaimer: Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings

per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for 2016 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche

Appendix: Tables

1.	Sales January to March 2016 and 2015	10
2.	Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015.....	11
3.	Pharmaceuticals Division.....	12
4.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2016 vs. Q1 2015.....	13
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth.....	14
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	15
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	16
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	17
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*	18

1. Sales January to March 2016 and 2015

CHF millions	Three months ended 31 March		% change	
	2016	2015	At CER	In CHF
Pharmaceuticals Division	9,800	9,322	4	5
United States	4,716	4,392	3	7
Europe	2,319	2,178	5	6
Japan	853	763	4	12
International*	1,912	1,989	4	-4
Diagnostics Division	2,614	2,511	5	4
Roche Group	12,414	11,833	4	5

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015

CHF millions	Q1 2015	% change	Q2 2015	% change	Q3 2015	% change	Q4 2015	% change	Q1 2016	% change
		vs. Q1 2014		vs. Q2 2014		vs. Q3 2014		vs. Q4 2014		vs. Q1 2015
Pharmaceuticals Division	9,322	4	9,028	7	9,340	6	9,641	3	9,800	4
United States	4,392	6	4,194	7	4,461	7	4,569	3	4,716	3
Europe	2,178	1	2,113	3	2,185	6	2,258	5	2,319	5
Japan	763	-2	777	18	801	8	883	2	853	4
International*	1,989	9	1,944	5	1,893	4	1,931	2	1,912	4
Diagnostics Division	2,511	6	2,724	7	2,600	4	2,979	7	2,614	5
Roche Group	11,833	5	11,752	7	11,940	6	12,620	4	12,414	4

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

3. Pharmaceuticals Division

Top-selling pharmaceuticals and recent new launches	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
January - March 2016										
MabThera/Rituxan	1,825	3	978	0	479	5	62	12	306	11
Herceptin	1,725	4	651	4	525	2	67	5	482	7
Avastin	1,706	4	775	-2	471	2	192	7	268	27
Perjeta	439	33	224	15	149	65	23	18	43	65
Actemra/RoActemra	386	14	145	12	131	17	60	14	50	10
Tamiflu	367	-6	251	-15	20	78	60	4	36	35
Xolair	356	22	356	22	-	-	-	-	-	-
Lucentis	355	-13	355	-13	-	-	-	-	-	-
Activase/TNKase	276	21	265	21	-	-	-	-	11	13
Tarceva	258	-14	136	-15	48	-18	22	0	52	-14
Recent new launches										
Kadcyla	201	11	79	-2	83	13	17	27	22	56
Esbriet	178	96	127	145	45	36	-	-	6	4
Zelboraf	53	-1	12	-2	32	-6	1	146	8	9
Erivedge	49	46	33	37	12	54	-	-	4	104
Gazyva/Gazyvaro	45	67	29	67	11	162	-	-	5	-7
Alecensa	29	161	10	**	-	-	19	66	-	-
Cotellic	11	**	2	**	9	**	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

** Over 500%

4. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2016 vs. Q1 2015

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	1,825	3	978	0	479	5	62	12	306	11
Herceptin	1,725	4	651	4	525	2	67	5	482	7
Avastin	1,706	4	775	-2	471	2	192	7	268	27
Perjeta	439	33	224	15	149	65	23	18	43	65
Actemra/RoActemra	386	14	145	12	131	17	60	14	50	10
Tamiflu	367	-6	251	-15	20	78	60	4	36	35
Xolair	356	22	356	22	-	-	-	-	-	-
Lucentis	355	-13	355	-13	-	-	-	-	-	-
Activase/TNKase	276	21	265	21	-	-	-	-	11	13
Tarceva	258	-14	136	-15	48	-18	22	0	52	-14
Kadcyla	201	11	79	-2	83	13	17	27	22	56
CellCept	189	-4	45	0	43	-3	15	11	86	-8
Esbriet	178	96	127	145	45	36	-	-	6	4
Pulmozyme	160	7	112	6	31	6	-	-	17	22
Mircera	118	0	-	-	21	-7	45	4	52	0
Xeloda	111	-17	5	-71	9	-31	25	12	72	-13
Rocephin	82	5	-	-	13	-13	6	-10	63	12
Pegasys	82	-50	11	-16	19	-40	1	-83	51	-55
NeoRecormon/Epogin	79	-14	-	-	36	-10	10	-12	33	-18
Valcyte/Cymevene	78	-21	19	-25	30	-26	-	-	29	-14

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2015	% change vs. Q1 2014	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015
MabThera/Rituxan	1,744	5	1,752	6	1,772	4	1,777	4	1,825	3
Herceptin	1,652	12	1,613	10	1,614	7	1,659	10	1,725	4
Avastin	1,619	6	1,644	13	1,705	8	1,716	9	1,706	4
Perjeta	322	82	337	64	376	57	410	50	439	33
Actemra/RoActemra	334	27	341	23	367	18	390	25	386	14
Tamiflu	376	6	41	61	118	46	170	-67	367	-6
Xolair	281	28	312	27	339	21	345	22	356	22
Lucentis	394	-9	375	-16	373	-18	378	-17	355	-13
Activase/TNKase	221	15	216	16	239	14	259	36	276	21
Tarceva	295	-3	307	-10	292	-7	287	-9	258	-14
Kadcyla	179	80	183	54	196	44	211	36	201	11
CellCept	197	-7	191	-1	194	-4	203	13	189	-4
Esbriet	88	-	141	-	157	-	177	296	178	96
Pulmozyme	146	4	160	15	166	14	180	8	160	7
Mircera	114	17	108	17	147	55	106	-1	118	0
Xeloda	136	-53	124	-29	124	-11	129	-9	111	-17
Rocephin	79	18	63	0	64	-8	73	-1	82	5
Pegasys	168	-39	117	-58	120	-45	133	-32	82	-50
NeoRecormon/Epogin	93	-10	89	-19	90	-8	94	-6	79	-14
Valcyte/Cymevene	100	-41	87	-47	83	-52	99	-41	78	-21

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2015	% change vs. Q1 2014	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015
MabThera/Rituxan	937	10	938	7	947	4	938	7	978	0
Herceptin	598	18	578	18	609	12	599	13	651	4
Avastin	761	6	741	11	784	6	772	11	775	-2
Perjeta	187	60	192	43	208	37	217	31	224	15
Actemra/RoActemra	124	35	129	30	144	21	153	32	145	12
Tamiflu	284	49	24	131	104	54	121	-74	251	-15
Xolair	281	28	312	27	339	21	345	22	356	22
Lucentis	394	-9	375	-16	373	-18	378	-17	355	-13
Activase/TNKase	210	16	206	18	228	15	246	36	265	21
Tarceva	154	2	165	-15	159	-7	160	1	136	-15
Kadcyla	78	-1	72	-2	79	6	79	12	79	-2
CellCept	43	-17	51	2	53	-14	54	29	45	0
Esbriet	50	-	98	-	114	-	124	*	127	145
Pulmozyme	102	4	109	15	115	9	128	19	112	6
Mircera	-	-	-	-	-	-	-	-	-	-
Xeloda	15	-89	16	-48	12	3	13	13	5	-71
Rocephin	-	-	-	-	-	-	-	-	-	-
Pegasys	12	-82	13	-84	17	-45	43	74	11	-16
NeoRecormon/Epogin	-	-	-	-	-	-	-	-	-	-
Valcyte/Cymevene	24	-76	16	-83	16	-86	33	-64	19	-25

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2015	% change vs. Q1 2014	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015
MabThera/Rituxan	452	1	443	-1	455	1	468	3	479	5
Herceptin	508	0	490	-1	502	0	510	4	525	2
Avastin	456	3	435	4	457	5	465	5	471	2
Perjeta	89	140	99	125	114	96	130	74	149	65
Actemra/RoActemra	110	24	114	21	120	19	129	23	131	17
Tamiflu	11	-83	1	478	1	-65	3	455	20	78
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tarceva	58	-15	56	-16	54	-20	52	-23	48	-18
Kadcyla	73	229	79	135	83	92	88	49	83	13
CellCept	44	-10	43	-9	44	-10	47	-1	43	-3
Esbriet	32	-	37	-	37	-	46	44	45	36
Pulmozyme	29	2	28	2	29	8	30	8	31	6
Mircera	22	-3	22	-3	21	-1	22	-4	21	-7
Xeloda	13	-59	9	-53	10	-41	10	-30	9	-31
Rocephin	15	14	8	-8	5	-15	9	-27	13	-13
Pegasys	31	-55	24	-58	24	-45	22	-45	19	-40
NeoRecormon/Epogin	39	-10	38	-11	38	-9	38	-6	36	-10
Valcyte/Cymevene	40	-2	37	-8	39	-1	36	-16	30	-26

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2015	% change vs. Q1 2014	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015
MabThera/Rituxan	52	1	55	28	59	7	64	9	62	12
Herceptin	60	-7	65	22	65	3	70	3	67	5
Avastin	167	4	182	29	189	13	208	12	192	7
Perjeta	18	12	21	21	22	18	23	14	23	18
Actemra/RoActemra	49	1	54	28	57	13	61	10	60	14
Tamiflu	54	-2	-1	-97	-	-	12	-75	60	4
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tarceva	20	-12	23	8	25	12	24	-1	22	0
Kadcyla	12	-	15	81	15	39	16	23	17	27
CellCept	12	-3	14	8	14	11	16	11	15	11
Esbriet	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	-	-	-	-	-	-	-	-	-
Mircera	40	-14	47	23	48	6	54	9	45	4
Xeloda	20	-8	22	22	22	8	25	10	25	12
Rocephin	7	-9	7	1	8	-2	7	-5	6	-10
Pegasys	6	-50	5	-73	2	-82	2	-84	1	-83
NeoRecormon/Epogin	11	-24	12	0	12	-7	12	-9	10	-12
Valcyte/Cymevene	-	-	-	-	-	-	-	-	-	-

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q1 2015	% change vs. Q1 2014	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015
MabThera/Rituxan	303	2	316	13	311	5	307	-2	306	11
Herceptin	486	23	480	14	438	9	480	16	482	7
Avastin	235	11	286	27	275	16	271	7	268	27
Perjeta	28	222	25	112	32	125	40	131	43	65
Actemra/RoActemra	51	55	44	8	46	15	47	31	50	10
Tamiflu	27	-20	17	18	13	22	34	73	36	35
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	11	-2	10	-10	11	-11	13	32	11	13
Tarceva	63	1	63	6	54	-1	51	-18	52	-14
Kadcyla	16	333	17	131	19	74	28	93	22	56
CellCept	98	-2	83	1	83	5	86	16	86	-8
Esbriet	6	-	6	-	6	-	7	114	6	4
Pulmozyme	15	9	23	34	22	49	22	-22	17	22
Mircera	52	99	39	24	78	206	30	-13	52	0
Xeloda	88	-17	77	-27	80	-11	81	-12	72	-13
Rocephin	57	25	48	2	51	-7	57	0	63	12
Pegasys	119	-8	75	-42	77	-40	66	-42	51	-55
NeoRecormon/Epogin	43	-6	39	-29	40	-8	44	-5	33	-18
Valcyte/Cymevene	36	4	34	-1	28	-17	30	-22	29	-14

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others